Clinical Significance of Expression of Topoisomerase 2а in Breast Cancer

Clinical Significance of Expression of Topoisomerase 2а in Breast Cancer

Topoisomerases are enzymes that control the topology of DNA. Topoisomerases are divided into types 1 and 2, depending on the mechanism of action. The article discusses the structure and mechanisms of the action of topoisomerases, the possibility of an independent value of the level of expression of...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. A. Samuseva, R. V. Lyubota, A. S. Zotov, R. I. Vereshchako
Format:	Article
Language:	Russian
Published:	LLC "Publishing House OKI" 2020-05-01
Series:	Антибиотики и Химиотерапия
Subjects:	breast cancer topoisomerase 2a anthracycline antibiotics
Online Access:	https://www.antibiotics-chemotherapy.ru/jour/article/view/52
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Prevention of Heart Failure Induced by Doxorubicin with Early Administration of Dexrazoxane (PHOENIX Study): dose response and time course of dexrazoxane-induced degradation of topoisomerase 2b
by: Hui-Ming Chang, et al.
Published: (2025-05-01)

Lipofilling as a method of reconstructive treatment of breast cancer patients (а review of literature)
by: R. V. Lyubota, et al.
Published: (2015-01-01)

Role of topoisomerase II α and Ki -67 biomarkers in pituitary tumors
by: Chhanda Das, et al.
Published: (2023-12-01)

DIAGNOSIS AND PREVENTION OF CARDIOTOXICITY IN PATIENTS WITH BREAST CANCER FROM THE STANDPOINT OF AN ONCOLOGIST AND A CARDIOLOGIST
by: T. Yu. Semiglazova, et al.
Published: (2017-09-01)

Synthesis, in vitro and in silico studies of a novel chrysin-ferrocene Schiff base with potent anticancer activity via G1 arrest, caspase-dependent apoptosis and inhibition of topoisomerase II
by: Mohammed Khaled Bin Break, et al.
Published: (2025-12-01)

Anti-topoisomerase 1 antibody level changes after B сell depletion therapy in systemic sclerosis
by: L. P. Ananyeva, et al.
Published: (2022-03-01)

Inhibitory action of exogenous cardiolipin on the bacterial type i and ii dna topoisomerases <i>in</i> <i>vitro</i>
by: Yu. L. Mikulovich, et al.
Published: (2012-08-01)

Creation of anthracycline prodrug
by: A. N. Tevyashova
Published: (2014-12-01)

The basic mechanisms the influence of metabolic syndrome on the risk and prognosis of breast cancer (review)
by: I. B. Schepotin, et al.
Published: (2014-07-01)

Effect of body mass index on clinical and morphological characteristics of triple negative breast cancer
by: I. B. Schepotin, et al.
Published: (2014-07-01)

CARDIOVASCULAR COMPLICATIONS CAUSED BY CHEMOTHERAPY AND TARGETED AGENTS
by: L. V. Bolotina, et al.
Published: (2016-01-01)

Clinical, Echocardiographic and Laboratory Cardiac Monitoring in Breast Cancer Patients Undergoing Chemotherapy with Anthracycline Agents: A Pilot Study on Cardioprotective Algorithms at Mohammad Hoesin General Hospital, Palembang
by: Indah Puspita
Published: (2025-07-01)

RADIONUCLIDE METHODS IN THE DETECTION AND FORECAST OF ANTHRACYCLINE-INDUCED CARDIOTOXICITY IN BREAST CANCER PATIENTS
by: V. I. Chernov, et al.
Published: (2016-12-01)

Randomized, Placebo‐Controlled, Triple‐Blind Clinical Trial of Ivabradine for the Prevention of Cardiac Dysfunction During Anthracycline‐Based Cancer Therapy
by: Stephanie Itala Rizk, et al.
Published: (2025-05-01)

Relationship between Chemotherapy and Atrial Fibrillation: Clinical Case
by: A. A. Avagimyan, et al.
Published: (2021-11-01)

Anthracycline-induced cardiac toxicity: A clinical review
by: Adil Abdelhameed Abbas, et al.
Published: (2019-01-01)

POSSIBILITIES OF IVABRADINE, A SELECTIVE INHIBITOR OF ION F-CHANNELS OF SINUS NODE, IN PREVENTION OF ANTHRACYCLINE CARDIOTOXICITY IN PATIENTS WITH BREAST CANCER
by: Yu. V. Vasyuk, et al.
Published: (2017-05-01)

Analysis of arterial stiffness parameters in breast cancer patients undergoing combination anthracycline-containing chemotherapy
by: E. G. Medvedeva, et al.
Published: (2025-05-01)

EXPERIENCE OF USING DAPTOMYCIN IN TREATMENT OF CHRONIC STERNAL OSTEOMYELITIS IN BREAST CANCER PATIENT: A CLINICAL CASE REPORT
by: Z. V. Grigorievskaya, et al.
Published: (2017-06-01)

Complexation reaction with Sm(III): a facile spectrophotometric quantification of daunorubicin in pharmaceutical preparation and biological fluids
by: Basima A. A. Saleem
Published: (2025-08-01)

MicroRNAs in anthracycline cardiotoxicity: biomarkers, mechanisms, and therapeutic advances
by: Hongyun Mao, et al.
Published: (2025-08-01)

Ischemic stroke as the first manifestation of anthracycline cardiomyopathy
by: G. R. Ramazanov, et al.
Published: (2023-01-01)

Biomarkers of interstitial lung disease in systemic scleroderma and their significance
by: D. V. Khorolsky, et al.
Published: (2023-02-01)

Allelic variant 6A (rs35068180) of the MMP-3 promoter region as a predictor of cardiotoxicity after the end of adjuvant chemotherapy with doxorubicin in patients with breast cancer
by: I. A. Karput, et al.
Published: (2024-02-01)

Cardiovascular system state changes in non-Hodgkin’s lymphoma patients during chemotherapy
by: A.-S. O. Bady, et al.
Published: (2020-05-01)

Cardiotoxicity of anticancer drugs and radiotherapy in patients with hematologic malignancies and solid tumors
by: L. M. Kogoniya, et al.
Published: (2022-07-01)

Clinical significance of androgen receptor in unilateral invasive breast cancer in women
by: Menghan Cao, et al.
Published: (2025-08-01)

The antimicrobial activity of exogeno us anionic phospholipids against Mycobacterium tuberculosis and Escherichia coli
by: Yu. L. Mikulovich, et al.
Published: (2016-06-01)

Significance of the inframammary crease for reconstruction of the breast and methods for its restoration (a review of literature)
by: I. F. Kamaletdinov, et al.
Published: (2015-11-01)

CLINICAL CHARACTERISTICS OF BREAST CANCER WITH STEROID RECEPTORS EXPRESSION AND HER2 AMPLIFICATION
by: F. V. Moiseenko, et al.
Published: (2017-02-01)

Prevention and treatment of anthracycline-induced cardiotoxicity: a systematic review and network meta-analysis of randomized controlled trials
by: Siyu Li, et al.
Published: (2025-07-01)

Cystic lymphangioma of the breast. First case in Russian clinical practice
by: A. D. Zikiryahodzhaev, et al.
Published: (2021-09-01)

Clinical significance and heterogeneity of circulating tumor cells and clusters in breast cancer subtypes
by: LiangYu Hao, et al.
Published: (2025-07-01)

Structural basis of topoisomerase targeting by delafloxacin
by: Shabir Najmudin, et al.
Published: (2025-07-01)

Nonmass lesions on preoperative MRI in breast cancer patients: clinical implications and prognostic significance
by: Joon Suk Moon, et al.
Published: (2025-05-01)

Prognostic significance of microcalcifications in breast cancer (literature review)
by: V. O. Aksenenko, et al.
Published: (2022-03-01)

Decreased expression of p53 is associated with down expression of zyxin in breast cancer
by: Rezvan Rostampour, et al.
Published: (2024-08-01)

Features of integrin subunit β4 expression depending on clinical and morphological parameters of breast cancer
by: M. V. Zavyalova, et al.
Published: (2025-04-01)

Morphometry in the cytological evaluation of breast lesions and its diagnostic significance
by: Sujata Jetley, et al.
Published: (2025-01-01)

Clinical case of torpid course of metastatic triple negative breast cancer
by: E. P. Kulikov, et al.
Published: (2022-03-01)